BUSINESS● LOWSep 8 · Sep 8, 2026, 5:54 PM
Beam drops after updating Phase 1/2 trial data for gene-editing drug
Seeking Alpha Tech · global
Beam's stock dropped after the company updated Phase 1/2 trial data for its gene-editing drug, reflecting investor reaction to the latest clinical information. This is significant for the company's valuation and pharmaceutical development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS13m agoGrifols S.A. reports Q3 results; says on track to meet its 2026 guidanceSeeking Alpha TechBUSINESS14m agoDisney targets up to 20% in cost savings, including job cuts – reportSeeking Alpha Tech